Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from AMGN

Leading drug maker Amgen (AMGN) delivered impressive second-quarter results. The company is well-positioned for solid long-term growth, driven by its diversified and growing product portfolio, rising demand from a rapidly aging population, and continued advancements in science and technology. Given its high profitability, attractive dividends, and bright growth prospects, we…

StockNews.com

Amgen is Our Growth Stock of the Week…

Biotech stocks are outperforming due to attractive valuations and strong catalysts. Amgen (AMGN) is one of the top stocks in the space due to its strong product portfolio, pipeline, and impressive management team. Read on to find out why it's our stock of the week.

StockNews.com

3 Biotech Stocks to Buy for Q4 and 1 to Avoid

Favorable federal investments are anticipated to fuel further expansion in the biotech industry. Given the sector’s good prospects, quality biotech stocks Amgen (AMGN), Gilead Sciences (GILD), and Biogen (BIIB) could be ideal buys. However, fundamentally weak stock Intra-Cellular Therapies (ITCI) might be best avoided. Read on….

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

3 Biotech Stocks That'll Make You Richer and 1 That Won't

The biotech industry continues to stay resilient to broader economic challenges. Moreover, the planned multi-million-dollar government investments should bode well for the industry. Hence, quality biotech stocks Amgen (AMGN), Gilead Sciences (GILD), and Biogen (BIIB) could be ideal buys to cash in on the industry’s prospects. However, fundamentally weak stock…

StockNews.com

Amgen Whale Trades Spotted

A whale with a lot of money to spend has taken a noticeably bearish stance on Amgen. Looking at options history for Amgen (NASDAQ:AMGN) we detected 22 strange trades.

Benzinga

2 Biotech Stocks to Buy and Hold for the Long Term

Intensive innovation, breakthrough developments, and growing investments should help the biotech industry witness solid growth over the next decade. And given the sector’s reputation as a safe haven amid economic turmoil, it could be wise for investors to buy and hold fundamentally solid biotech stocks Amgen (AMGN) and AstraZeneca (AZN)…

StockNews.com

5 Income Stocks to Turn to When Times Are Tough

The S&P 500 is coming off its four-week win streak amid signals of cooling price increases. However, inflation is still running hot near a 40-year high, which might induce the Fed to continue its policy rate hikes. We think income stocks AbbVie (ABBV), Amgen (AMGN), Pfizer (PFE), Bristol-Myers Squibb (BMY),…

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

5 Biotech Stocks in the Buy Zone This Week

The biotech industry is expected to see solid growth in the long term due to rising healthcare spending, breakthrough developments, and an aging population. Given the industry’s solid growth prospects and non-cyclical nature, it could be wise to invest in fundamentally strong biotech stocks Gilead Sciences (GILD), Biogen (BIIB), Jazz…

StockNews.com

Dogs of the Dow: 2 Stocks to Buy and 2 to Hold

The stock market has rebounded lately from the decline in the year's first half, thanks to better-than-expected corporate earnings and the expectation of easing inflationary pressure. However, a still uncomfortable inflation level and the possible aggressive rate hikes could keep the market volatile. The Dogs of the Dow investment strategy…

StockNews.com

This Is What Whales Are Betting On Amgen

A whale with a lot of money to spend has taken a noticeably bullish stance on Amgen. Looking at options history for Amgen (NASDAQ:AMGN) we detected 10 strange trades.

Benzinga

What Are Whales Doing With Amgen

Someone with a lot of money to spend has taken a bearish stance on Amgen (NASDAQ:AMGN). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

5 Biotech Stocks to Buy and Hold for the Next Decade

The biotech industry seems poised to witness solid growth over the next decade with intensive innovation, breakthrough developments, and growing investments in the sector. So, given analysts’ promising growth outlook for the industry, it could be wise for investors to buy and hold fundamentally solid biotech stocks Vertex Pharmaceuticals (VRTX),…

StockNews.com

1 Biotech Stock That Stands out From the Rest

Amgen (AMGN) has undertaken several strategic growth initiatives to capitalize on the expanding biotech industry. In addition, several FDA drug approvals and other research and development breakthroughs make it well-positioned to witness significant growth in the near term, making it an ideal candidate for investors seeking to gain exposure in…

StockNews.com

3 Biotech Stocks to Beat the Bear Market

2022 is a challenging year for the market. After battling surging inflation for the first six months, another threat is emerging with rising recession risk. Biotech stocks could be a place where investors can find outperformance given their low valuations and strong long-term fundamentals.

StockNews.com

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Amgen Whale Trades For July 12

StockNews.com

Amgen is Our Growth Stock of the Week…

Benzinga

Check Out What Whales Are Doing With AMGN

StockNews.com

4 "Strong Buy" Biotech Stocks to Add to Your Watchlist

As the Biotech industry’s role in finding cures for chronic diseases and critical conditions is expected to keep attracting investors’ attention, it could be wise to scoop up shares of the fundamentally-strong biotech companies Vertex Pharmaceuticals (VRTX), United Therapeutics (UTHR), Amgen (AMGN), and Sino Biopharmaceutical (SBHMY) because of their solid…

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

5 "Strong Buy" Pharmaceutical Stocks to Own for the Long Haul

The inelastic demand and rising investments in research and development should drive the pharmaceutical industry’s growth in the long run. Therefore, pharmaceutical stocks AbbVie (ABBV), Amgen (AMGN), Catalyst (CPRX), Novo Nordisk (NVO), and Vertex (VRTX), which possess sound fundamentals, could be solid long-term investments. These stocks are rated Strong Buy…

Benzinga

$100 Invested In Amgen 15 Years Ago Would Be Worth This Much Today

Amgen (NASDAQ:AMGN) has outperformed the market over the past 15 years by 3.97% on an annualized basis producing an average annual return of 10.41%. Currently, Amgen has a market capitalization of $130.40 billion.

StockNews.com

3 Biotech Stocks to Buy Now

Biotech stocks are starting to move higher as longer-term rates decline. The sector is very cheap with strong long-term fundamentals. Amgen (AMGN), Biogen (BIIB), and Bio-Techne (TECH) are 3 top biotech stocks that investors should consider buying.

StockNews.com

2 Red-Hot Dow Jones Stocks With More Room to Run

Recessionary concerns and the Fed’s hawkish policy measures to combat high inflation are expected to extend the market correction. However, certain Dow Jones constituents with solid financials and bright growth prospects have been outperforming the benchmark index. So, Verizon (VZ) and Amgen (AMGN) could be solid investments now.

Benzinga

$100 Invested In Amgen 20 Years Ago Would Be Worth This Much Today

Amgen (NASDAQ:AMGN) has outperformed the market over the past 20 years by 2.03% on an annualized basis producing an average annual return of 9.14%. Currently, Amgen has a market capitalization of $131.14 billion.

StockNews.com

Dogs of the Dow: 4 Stocks to Buy Now

Market sentiment was mostly unchanged on Monday, as investors await the May inflation report. Given the market uncertainties, we think investing in high-yielding dividend stocks that are part of the Dow Jones index—commonly known as the Dogs of the Dow—might the ideal strategy now. And our top choices among these…

Benzinga

$100 Invested In Amgen 15 Years Ago Would Be Worth This Much

Amgen (NASDAQ:AMGN) has outperformed the market over the past 15 years by 3.74% on an annualized basis producing an average annual return of 10.5%. Currently, Amgen has a market capitalization of $136.00 billion.

1 … 3 4 5 6

People

Dipanjan BanchurSince

722 stories

Mangeet Kaur BounsMangeet

595 stories

Jaimini DesaiJaimini

62 stories

Jaimini DesaiJaimini Desai

59 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Dow Jones Industrial Average

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.